A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Phase 1 Completed 24 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.

Timeline

Start: 2006-07-28
Primary completion: 2008-02-20
Completion: 2008-02-20

Publications

Background Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Caffeine	Small molecule	200 mg	Oral
Subject	Dextromethorphan	Unknown	30 mg	Oral
Subject	Midazolam	Small molecule	3 mg	Oral
Subject	Omeprazole	Other / unclassified	40 mg	Oral
Subject	Pazopanib	Small molecule	800 mg	Oral
Subject	Warfarin	Small molecule	10 mg	Oral

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Summary

Timeline

Publications

Drugs

Indications